Table 1 Demographic results of Locomo test and characteristics according to the Locomo stage
All patients (n = 76) | Non-locomo (n = 4) | Locomo stage 1 (n = 19) | Locomo stage 2 (n = 53) | P value | |||||
|---|---|---|---|---|---|---|---|---|---|
Male, n (%) | 52 (68) | 4 (100) | 14 (74) | 34 (64) | .28 | ||||
Age (years) | 67.5 (59.3–76.8) | 59.5 (50.8–62.3) | 62.0 (56.0–72.0) | 72.0 (64.5–79.5) | .005 | ||||
Stand-up test, n (%) | |||||||||
Difficulty standing from | |||||||||
40-cm-high seat (either leg) | 37 (49) | 0 (0) | 12 (63) | 27 (51) | < .001 | ||||
20-cm-high seat (both legs) | 23 (30) | 0 (0) | 0 (0) | 23 (43) | |||||
Two-step test | |||||||||
< 1.3, n (%) | 22 (29) | 0 (0) | 16 (84) | 6 (11) | < .001 | ||||
< 1.1, n (%) | 44 (58) | 0 (0) | 0 (0) | 44 (83) | |||||
GLFS-25 score | |||||||||
≥ 7, n (%) | 25 (33) | 0 (0) | 10 (53) | 15 (28) | < .001 | ||||
≥ 16, n (%) | 33 (43) | 0 (0) | 0 (0) | 33 (62) | |||||
Active VD use, n (%) | 60 (79) | 4 (100) | 15 (79) | 41 (77) | .56 | ||||
L-carnitine use, n (%) | 17 (22) | 2 (50) | 5 (26) | 10 (19) | .31 | ||||
Dialysis vintage (years) | 7 (2–14) | 16 (2–29) | 7 (4–18) | 6 (2–14) | .80 | ||||
Primary cause of ESRD, n (%) | |||||||||
Diabetes mellitus | 29 (38) | 1 (25) | 7 (37) | 21 (40) | .39 | ||||
Chronic glomerulonephritis | 37 (49) | 2 (50) | 12 (63) | 23 (43) | |||||
Renal sclerosis | 6 (8) | 1 (25) | 0 (0) | 5 (9) | |||||
Other | 4 (5) | 0 (0) | 0 (0) | 4 (8) | |||||
Kt/V | 1.53 (1.36–1.67) | 1.41 (1.33–1.52) | 1.45 (1.32–1.67) | 1.55 (1.45–1.68) | .10 | ||||